Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

Robert F. Kennedy Jr. clinched the political support needed to become the nation’s top health official by pledging to work ...

Regulators will soon “unleash a massive framework” for how vaccines are tested and approved, according to FDA Commissioner ...

Key Takeaways The S&P 500 eked out a gain of 0.1% on Monday, May 19, 2025, as investors weighed the implications of Moody's ...

Health-care companies rose as some beaten-down stocks recouped some of their losses. UnitedHealth Group rose by more than 7%, but remain more than one-third lower for the year to date. Similarly, ...

The LP.8.1 variant of the SARS-CoV-2 virus differs from the JN.1 family that previous vaccines had been designed to target, ...

The vaccine, Nuvaxovid, is the third coronavirus shot to gain full approval, joining vaccines from Pfizer and Moderna. It has ...

U.S. stocks finished near the unchanged mark on Monday with market sentiment weakened by the downgrade of the federal ...

Market Domination hosts Josh Lipton and Julie Hyman go over some of the day's top trending tickers. Novavax (NVAX) stock is ...

The FDA has approved Novavax’s protein-based COVID-19 vaccine, giving some Americans another option besides messenger RNA vaccines to prevent SARS-CoV-2 infection.

Novavax today announced that the US Food and Drug Administration (FDA) has approved full licensure for its COVID-19 vaccine, ...

The FDA has approved Novavax’s COVID-19 vaccine, Nuvavoxid, for use in adults 65 and older and in individuals ages 12-64 who have at least one underlying health condition. The approval is based on ...